BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23091305)

  • 1. IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome.
    Li S; Yu M; Li H; Zhang H; Jiang Y
    Mediators Inflamm; 2012; 2012():260473. PubMed ID: 23091305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence of altered Th17 pathway signatures in the cerebrospinal fluid of patients with Guillain Barré Syndrome.
    Debnath M; Nagappa M; Dutta D; Talukdar PM; Subbanna M; Shivakumar V; Wahatule R; Sinha S; Bindu PS; Periyavan S; Umamaheswara Rao GS; Kumar MA; Taly AB
    J Clin Neurosci; 2020 May; 75():176-180. PubMed ID: 32217048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome.
    Han RK; Cheng YF; Zhou SS; Guo H; He RD; Chi LJ; Zhang LM
    J Clin Immunol; 2014 Jan; 34(1):94-103. PubMed ID: 24217817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barré syndrome and downregulated by IVIg treatments.
    Li S; Jin T; Zhang HL; Yu H; Meng F; Concha Quezada H; Zhu J
    Mediators Inflamm; 2014; 2014():740947. PubMed ID: 24899787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered serum levels of IL-36 cytokines (IL-36α, IL-36β, IL-36γ, and IL-36Ra) and their potential roles in Guillain-Barré syndrome.
    Zhao Z; Zhang R; Gao X; Li H; Liu H
    Medicine (Baltimore); 2020 Dec; 99(52):e23832. PubMed ID: 33350771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated levels of cerebrospinal fluid and plasma interleukin-37 in patients with Guillain-Barré syndrome.
    Li C; Zhao P; Sun X; Che Y; Jiang Y
    Mediators Inflamm; 2013; 2013():639712. PubMed ID: 24174711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
    Zhang HL; Zhang XM; Mao XJ; Deng H; Li HF; Press R; Fredrikson S; Zhu J
    Acta Neurol Scand; 2012 Feb; 125(2):129-35. PubMed ID: 21434877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-23 and IL-27 Levels in Serum are Associated with the Process and the Recovery of Guillain-Barré Syndrome.
    Peng J; Zhang H; Liu P; Chen M; Xue B; Wang R; Shou J; Qian J; Zhao Z; Xing Y; Liu H
    Sci Rep; 2018 Feb; 8(1):2824. PubMed ID: 29434217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated levels of S100B, tau and pNFH in cerebrospinal fluid are correlated with subtypes of Guillain-Barré syndrome.
    Wang XK; Zhang HL; Meng FH; Chang M; Wang YZ; Jin T; Mix E; Zhu J
    Neurol Sci; 2013 May; 34(5):655-61. PubMed ID: 22526766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of serum interleukin-27 and interleukin-35 concentrations in patients with Guillain-Barré syndrome.
    Zhang LJ; Guo HY; Zhang DQ; Wang R; Li T; Li LM; Suo DM; Yang L
    Clin Chim Acta; 2017 May; 468():5-9. PubMed ID: 28167198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay.
    Kmezic I; Gustafsson R; Fink K; Svenningsson A; Samuelsson K; Ingre C; Olsson T; Hansson M; Kockum I; Adzemovic MZ; Press R
    Front Immunol; 2023; 14():1241199. PubMed ID: 38077366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
    Press R; Pashenkov M; Jin JP; Link H
    J Clin Immunol; 2003 Jul; 23(4):259-67. PubMed ID: 12959218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms of IL-17 and ICAM-1 and their expression in Guillain-Barré syndrome.
    Kharwar NK; Prasad KN; Singh K; Paliwal VK; Modi DR
    Int J Neurosci; 2017 Aug; 127(8):680-687. PubMed ID: 27595159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in Guillain-Barré syndrome.
    Liang SL; Wang WZ; Huang S; Wang XK; Zhang S; Wu Y
    Immunopharmacol Immunotoxicol; 2012 Dec; 34(6):1039-46. PubMed ID: 22738814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.
    Maimone D; Annunziata P; Simone IL; Livrea P; Guazzi GC
    J Neuroimmunol; 1993 Aug; 47(1):55-61. PubMed ID: 8376548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential biomarkers identified by tandem mass tags based quantitative proteomics for diagnosis and classification of Guillain-Barré syndrome.
    Ding Y; Shi Y; Wang L; Li G; Osman RA; Sun J; Qian L; Zheng G; Zhang G
    Eur J Neurol; 2022 Apr; 29(4):1155-1164. PubMed ID: 34913222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitigated Tregs and augmented Th17 cells and cytokines are associated with severity of experimental autoimmune neuritis.
    Wang X; Zheng XY; Ma C; Wang XK; Wu J; Adem A; Zhu J; Zhang HL
    Scand J Immunol; 2014 Sep; 80(3):180-90. PubMed ID: 24910360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrathecal anti-alphaB-crystallin IgG antibody responses: potential inflammatory markers in Guillain-Barré syndrome.
    Wanschitz J; Ehling R; Löscher WN; Künz B; Deisenhammer F; Kuhle J; Budka H; Reindl M; Berger T
    J Neurol; 2008 Jun; 255(6):917-24. PubMed ID: 18712293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th17 pathway signatures in a large Indian cohort of Guillain Barré syndrome.
    Debnath M; Nagappa M; Subbanna M; Sundaravadivel P; Talukdar PM; Shivakumar V; Wahatule R; Dutta D; Binukumar B; Sinha S; Bindu PS; Periyavan S; Umamaheswara Rao GS; Taly AB
    J Neuroimmunol; 2018 Oct; 323():125-130. PubMed ID: 30196825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barré syndrome.
    Li C; Luo T; Cheng Y; Liu S; Qiao L; Wu X; Liu K
    Neurol Sci; 2020 Feb; 41(2):295-303. PubMed ID: 31494821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.